Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review
Open Access
- 16 May 2014
- journal article
- review article
- Published by Wiley in BJOG: An International Journal of Obstetrics and Gynaecology
- Vol. 121 (10), 1210-1218
- https://doi.org/10.1111/1471-0528.12737
Abstract
Background Pregnant and postpartum women with severe hypertension are at increased risk of stroke and require blood pressure (BP) reduction. Parenteral antihypertensives have been most commonly studied, but oral agents would be ideal for use in busy and resource-constrained settings. Objectives To review systematically, the effectiveness of oral antihypertensive agents for treatment of severe pregnancy/postpartum hypertension. Search strategy A systematic search of MEDLINE, EMBASE and the Cochrane Library was performed. Selection criteria Randomised controlled trials in pregnancy and postpartum with at least one arm consisting of a single oral antihypertensive agent to treat systolic BP >= 160 mmHg and/or diastolic BP >= 110 mmHg. Data collection and analysis Cochrane REVMAN 5.1 was used to calculate relative risk (RR) and weighted mean difference by random effects. Main results We identified 15 randomised controlled trials (915 women) in pregnancy and one postpartum trial. Most trials in pregnancy compared oral/sublingual nifedipine capsules (8-10 mg) with another agent, usually parenteral hydralazine or labetalol. Nifedipine achieved treatment success in most women, similar to hydralazine (84% with nifedipine; relative risk [RR] 1.07, 95% confidence interval [95% CI] 0.98-1.17) or labetalol (100% with nifedipine; RR 1.02, 95% CI 0.95-1.09). Less than 2% of women treated with nifedipine experienced hypotension. There were no differences in adverse maternal or fetal outcomes. Target BP was achieved similar to 50% of the time with oral labetalol (100 mg) or methyldopa (250 mg) (47% labetelol versus 56% methyldopa; RR 0.85 95% CI 0.54-1.33). Conclusions Oral nifedipine, and possibly labetalol and methyldopa, are suitable options for treatment of severe hypertension in pregnancy/postpartum.Funding Information
- Bill and Melinda Gates Foundation (OPP1017337)
This publication has 41 references indexed in Scilit:
- Saving Mothers’ Lives: Reviewing maternal deaths to make motherhood safer: 2006–2008BJOG: An International Journal of Obstetrics and Gynaecology, 2011
- Antenatal magnesium sulphate may prevent cerebral palsy in preterm infants-but are we convinced? Evaluation of an apparently conclusive meta-analysis with trial sequential analysisBJOG: An International Journal of Obstetrics and Gynaecology, 2010
- Combination therapy in hypertensionJournal of the American Society of Hypertension, 2010
- Guidelines for the management of hypertensive disorders of pregnancy 2008Australian and New Zealand Journal of Obstetrics and Gynaecology, 2009
- Prevalence of Asthma and Allergic Rhinitis Among School Children of Karachi, Pakistan, 2007Journal of Asthma, 2009
- Stroke and Severe Preeclampsia and Eclampsia: A Paradigm Shift Focusing on Systolic Blood PressureObstetrics & Gynecology, 2005
- Antihypertensive Drug Effects on Placental Flow Velocity Waveforms in Pregnant Women with Severe HypertensionAustralian and New Zealand Journal of Obstetrics and Gynaecology, 1992
- Randomized, Controlled Trial of Hydralazine Versos Nifedipine in Preeclamptic Women with Acute HypertensionClinical and Experimental Hypertension. Part B: Hypertension in Pregnancy, 1992
- A double-blind, crossover study of acebutolol and hydrochlorothiazide/amiloride diuretic in Sudanese patients with essential hypertensionCurrent Medical Research and Opinion, 1982